Comparative Pharmacology
Head-to-head clinical analysis: PROLIXIN ENANTHATE versus PROMAPAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROLIXIN ENANTHATE versus PROMAPAR.
PROLIXIN ENANTHATE vs PROMAPAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluphenazine (the active entity of PROLIXIN ENANTHATE) is a phenothiazine antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic and mesocortical pathways. It also exhibits alpha-adrenergic blocking and anticholinergic effects.
PROMAPAR is a brand name for tramadol, a centrally acting analgesic that binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake, modulating pain perception.
12.5-50 mg intramuscularly every 1-3 weeks. Initial dose: 2.5-12.5 mg IM as a test dose; gradual titration based on response and tolerability.
5 mg orally twice daily, titrated up to maximum 60 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life approximately 11-15 days due to slow release from intramuscular depot; requires monitoring for prolonged effects after discontinuation
Terminal elimination half-life is 2-4 hours (mean 3 hours) in adults with normal renal function; prolonged to 8-15 hours in moderate-to-severe renal impairment.
Primarily renal (30-40% as metabolites, <1% unchanged) and biliary/fecal (15-20%)
Primarily renal (70-80% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal elimination accounts for approximately 20%.
Category C
Category C
Antipsychotic
Antipsychotic